Literature DB >> 16707236

Duration of immunity for canine and feline vaccines: a review.

Ronald D Schultz1.   

Abstract

In our studies aimed at assessing the minimum duration of vaccinal immunity (DOI), approximately 1000 dogs have been vaccinated with products from all the major US veterinary biological companies. The DOI for the various products is determined by antibody titers for all dogs and, by challenge studies in selected groups of dogs. Recently, all major companies that make canine vaccines for the U.S. market have completed their own studies; published data show a 3 years or longer minimum DOI for the canine core products, canine distemper virus (CDV), canine parvovirus type 2 (CPV-2), and canine adenovirus-2 (CAV-2). Studies with feline core vaccines - feline parvovirus (FPV), calicivirus (FCV) and herpes virus type I (FHV-1) have shown a minimum DOI of greater than 3 years. Based on these results, the current canine and feline guidelines (which recommend that the last dose of core vaccines be given to puppies and kittens > or =12 weeks of age or older, then revaccination again at 1 year, then not more often than every 3 years) should provide a level of protection equal to that achieved by annual revaccination. In contrast, the non-core canine and feline vaccines, perhaps with the exception of feline leukaemia vaccines, provide immunity for < or =1 year. In general the effectiveness of the non-core products is less than the core products. Thus, when required, non-core vaccines should be administered yearly, or even more frequently.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16707236     DOI: 10.1016/j.vetmic.2006.04.013

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  28 in total

1.  Important features of modified live virus vaccines - A comment.

Authors:  W Jean Dodds
Journal:  Can Vet J       Date:  2014-07       Impact factor: 1.008

2.  WSAVA Guidelines for the vaccination of dogs and cats.

Authors:  M J Day; M C Horzinek; R D Schultz; R A Squires
Journal:  J Small Anim Pract       Date:  2016-01       Impact factor: 1.522

3.  One Health approach to cost-effective rabies control in India.

Authors:  Meagan C Fitzpatrick; Hiral A Shah; Abhishek Pandey; Alyssa M Bilinski; Manish Kakkar; Andrew D Clark; Jeffrey P Townsend; Syed Shahid Abbas; Alison P Galvani
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-20       Impact factor: 11.205

4.  Discovery and characterization of mammalian endogenous parvoviruses.

Authors:  Amit Kapoor; Peter Simmonds; W Ian Lipkin
Journal:  J Virol       Date:  2010-10-13       Impact factor: 5.103

5.  Canine parvovirus: current perspective.

Authors:  S Nandi; Manoj Kumar
Journal:  Indian J Virol       Date:  2010-09-03

Review 6.  DNA vaccines in veterinary use.

Authors:  Laurel Redding; David B Weiner
Journal:  Expert Rev Vaccines       Date:  2009-09       Impact factor: 5.217

7.  Human bocaviruses are highly diverse, dispersed, recombination prone, and prevalent in enteric infections.

Authors:  Amit Kapoor; Peter Simmonds; Elizabeth Slikas; Linlin Li; Ladaporn Bodhidatta; Orntipa Sethabutr; Henda Triki; Olfa Bahri; Bamidele S Oderinde; Marycelin M Baba; David N Bukbuk; John Besser; Joanne Bartkus; Eric Delwart
Journal:  J Infect Dis       Date:  2010-06-01       Impact factor: 5.226

8.  Identification and characterization of a new bocavirus species in gorillas.

Authors:  Amit Kapoor; Natasha Mehta; Frank Esper; Mateja Poljsak-Prijatelj; Phenix-Lan Quan; Natasha Qaisar; Eric Delwart; W Ian Lipkin
Journal:  PLoS One       Date:  2010-07-23       Impact factor: 3.240

9.  Modeling the geographic spread of rabies in China.

Authors:  Jing Chen; Lan Zou; Zhen Jin; Shigui Ruan
Journal:  PLoS Negl Trop Dis       Date:  2015-05-28

10.  Recommendations on vaccination for Latin American small animal practitioners: a report of the WSAVA Vaccination Guidelines Group.

Authors:  M J Day; C Crawford; M Marcondes; R A Squires
Journal:  J Small Anim Pract       Date:  2020-03-30       Impact factor: 1.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.